Galectin-3 and Acute Heart Failure: Genetic Polymorphisms, Plasma Level, Myocardial Fibrosis and 1-year Outcomes

This study sought to investigate the relationship between galectin-3 (Gal-3), myocardial fibrosis (MF) and outcomes in acute heart failure. The single-nucleotide polymorphisms (SNPs) of at rs4644 and rs4652, plasma Gal-3 level, MF and major adverse events (MAEs) were obtained. There was no significant difference in MAEs when categorizing patients by the SNPs at rs4644 and rs4652. The circulating Gal-3 was related to the degree of MF (p < 0.001). Plasma Gal-3 level and MF can predict an increased risk of MAEs (p < 0.001, p = 0.023, respectively). Not the SNPs of but Gal-3 and MF can predict MAEs in acute heart failure at 1 year of follow-up.